By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Media HydeMedia Hyde
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Font ResizerAa
Media HydeMedia Hyde
Font ResizerAa
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Follow US
© 2026 Media Hyde Network. All Rights Reserved.
Health

The Number Of HIV Patients Worldwide Has Reached 48 Million

Last updated: December 3, 2025 4:28 am
Neha Ashraf
Share
SHARE

According to the World Health Organization (WHO), the number of people infected with the human immunodeficiency virus (HIV) worldwide has reached 48 million, with the Middle East and North Africa being the regions with the highest number of affected individuals.

‎According to the WHO, out of the 48 million people, 610,000 reside in the Middle East and North Africa, where the number of annual new infections has nearly doubled in at least a decade.

‎According to the organization, in these regions, 37,000 people were infected with the virus in 2016, and their number increased to 72,000 in 2024. In the region, at least four out of ten people are aware of their HIV status, while only one in three individuals is receiving treatment.

‎According to the organization, the AIDS response is entering a critical phase. Global funding dedicated to HIV is decreasing, which is putting decades of progress at risk.

‎WHO stated that HIV has now become a chronic, treatable infection, but to achieve the goal of ending AIDS by 2030, there is an urgent need to increase funding and strengthen HIV services.

‎The World Health Organization warned that the reduction in global funding will lead to an increase in new HIV infections and deaths, put greater pressure on healthcare systems, and leave the 2030 target of ending AIDS unfulfilled.

‎The organization also emphasized using artificial intelligence (AI) for the early diagnosis and treatment of HIV.

‎It is worth noting that HIV is a virus that attacks the body’s immune system, particularly destroying white blood cells, which weakens the immunity of the infected person.

‎There is no cure for HIV infection; however, effective HIV prevention, diagnosis, treatment of symptoms, and treatment of other infections can help keep HIV under control and potentially prevent it from progressing to AIDS.

Share This Article
Email Copy Link Print
Previous Article Increase In Dengue Cases Reported Across Punjab Including Lahore
Next Article Mohammad Nawaz Becomes Pakistan’s Best T20 Performer of 2025 Mohammad Nawaz Becomes Pakistan’s Best T20 Performer of 2025
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sponsored Ads

Stay Connected

FacebookLike
XFollow
InstagramFollow
YoutubeSubscribe
WhatsAppFollow
ThreadsFollow
Ukrainian drone evades Russian helicopter fire to strike oil tanker
Ukrainian drone evades Russian helicopter fire to strike oil tanker
Headline Politics
September 14, 2026
Six killed, 130 missing after Indonesian passenger ship capsizes
Six killed, 130 missing after Indonesian passenger ship capsizes
Court & Crime Headline
September 14, 2026
Iran Expected to Meet With Gulf Arab States as Mideast Conflict Widens
Iran Expected to Meet With Gulf Arab States as Mideast Conflict Widens
Headline Politics
September 14, 2026
Kosovo approves new government after months of political deadlock
Kosovo approves new government after months of political deadlock
Headline Politics
September 14, 2026
World leaders gather in New Delhi for final day of BRICS summit
World leaders gather in New Delhi for final day of BRICS summit
Headline Politics
September 14, 2026
Syrian child killed after roadside object explodes near Damascus
Syrian child killed after roadside object explodes near Damascus
Court & Crime Headline
September 14, 2026

You Might Also Like

Breathing Exercises in Yoga Help Control Blood Pressure, Study Finds
BlogHealth

Breathing Exercises in Yoga Help Control Blood Pressure, Study Finds

By
Misbah Jogyat
Health

Drug Testing Lab Declares Multiple Medicine Batches Unsafe, Bans Usage

By
Neha Ashraf
WASHINGTON: UnitedHealth has warned that the Trump administration’s planned Medicare obesity-drug pilot faces “notable challenges,” casting doubt over how smoothly the program can move ahead if major insurers stay cautious. Recent market reporting said the model depends heavily on participation from Medicare drug plans that cover most Part D enrollees, which makes the stance of large insurers especially important. The concern centers on a broader CMS effort to expand access to GLP-1 weight-loss medicines for seniors. Under CMS’s published framework, the longer-term BALANCE Model would begin in Medicare Part D in January 2027, while a temporary Medicare GLP-1 Bridge is designed to start earlier and give eligible beneficiaries short-term access before that main model begins. What makes this a little more complicated is that the short-term bridge and the longer pilot are not the same thing. CMS says the Medicare GLP-1 Bridge operates outside the normal Part D coverage and payment flow, meaning Part D sponsors are not directly involved in that bridge arrangement. In other words, insurer participation is a much bigger issue for the 2027 BALANCE rollout than for the bridge itself. That distinction matters because investors and drugmakers are watching this closely. Reports said shares of obesity-drug makers fell after UnitedHealth’s comments, largely because Medicare coverage is seen as a huge growth opportunity for drugs such as Wegovy and Zepbound. If major insurers hesitate, the program could struggle to achieve the scale CMS appears to want. There is already some evidence of resistance. MarketWatch reported that CVS Health has opted out, while UnitedHealth is still evaluating the structure and discussing possible changes with Medicare officials. That does not mean the program is dead, not yet anyway, but it does suggest the administration may need to revise the design or sweeten the terms if it wants broader insurer buy-in. The bigger backdrop here is cost. Medicare has long been wary of broad obesity-drug coverage because GLP-1 therapies are expensive and potentially involve very large patient populations. Earlier policy debates around these drugs were shaped by concerns that wide coverage could drive up federal spending sharply, even as supporters argued the medicines could reduce longer-term health costs tied to obesity. So the headline problem for CMS is pretty straightforward: it has created a short-term bridge that can move without direct Part D plan involvement, but the more ambitious long-term Medicare model still appears to need insurers on board. UnitedHealth’s warning does not shut the door, but it does signal that one of the industry’s biggest players thinks the current setup may not be ready for easy launch.
HeadlineHealth

UnitedHealth raises red flags over Medicare obesity-drug pilot

By
Mabruka Khan
Health

PMDC Holds NRE Exam for Foreign Medical, Dental Graduates on Sunday, 14 Dec

By
Irma Khan
Media Hyde Media Hyde Dark
Facebook Twitter Youtube Rss Medium

About US

Media Hyde Network: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 News.

Top Categories
  • Headline
  • Politics
  • Entertainment
  • Education
  • Sports
  • Religious
  • Metropolitan
  • Climate and Weather
Usefull Links
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Cookies Policy
  • Advertising Policy
  • Terms & Conditions

© 2025 Media Hyde Network. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?